BoomRx for cash-pay clinics: how the economics work

Landed cost in a cash-pay clinic is the per-vial drug cost plus the $30 flat-rate cold-chain shipping fee and any other charges on the order. BoomRx positions itself on competitive pricing across a national 503A, 503B, and brand partner network, which is attractive for high-volume clinics — but because rates are confirmed after signup, the clinic verifies the all-in number during onboarding rather than reading it off a public catalog. The practical questions are what the per-vial rate is on your top SKUs, how the $30 shipping fee applies across multi-line orders, and whether competitive pricing holds across refill cycles.

For a cash-pay model, predictability matters as much as the headline rate. A competitive price that shifts, or shipping and fees that are not visible per order, makes it hard to set a stable patient price. So the economic evaluation of BoomRx is less about whether the rates are competitive and more about how clearly and consistently the all-in landed cost is surfaced over time.

Fizy Health takes a pass-through approach built for cash-pay margin. It shows resolved 503A per-vial cost on every catalog and cart line before checkout, with a disclosed facilitation fee at payment — so the owner sets patient prices on the same number the clinic will actually pay, and the prescriber can quote at the visit on live cost. There is no per-vial markup layer hidden inside a negotiated rate; the drug cost passes through and the platform fee is stated.

On the operations side, one clinic cart batches the refill day and cart validation catches invalid SIGs, prescriber state mismatches, and stock gaps before payment, so the clinic stops paying for orders that get rejected after checkout. For a cash-pay clinic, the combined effect is margin you can see before you order and fewer surprises that quietly erode the spread.